2011-01-19 14:00:00 CET

2011-01-19 14:00:54 CET


REGULATED INFORMATION

English
Biotie Therapies - Major shareholder announcements

Notification according to Chapter 2, Section 10 of the Finnish Securities Market Act


BIOTIE THERAPIES CORP.    STOCK EXCHANGE RELEASE 19 January 2011 at 3 p.m.

Notification according to Chapter 2, Section 10 of the Finnish Securities Market
Act

Biotie Therapies Corp. ("Company") has gained knowledge of the notification
regarding the following change in holdings in accordance with Chapter 2, Section
9 of the Finnish Securities Markets Act.

Burrill Life Sciences Capital Fund, L.P. has notified Company that as a result
of the transactions carried out on 3 January 2011, certain change in holdings of
the Company's shares has taken place.

As a result of these transactions, the aggregate holdings of Burrill Life
Sciences Capital Fund, L.P. has decreased below 5 per cent of the total number
of shares and votes of the Company. Also the holdings of the General Partner,
Burrill & Company (Life Sciences GP), LLC of Burrill Life Sciences Capital Fund,
L.P has decreased below 5 per cent of the total number of shares and votes of
the Company.

The change in holdings in accordance with Chapter 2, Section 9 of the Finnish
Securities Markets Act of which the Company has gained knowledge of is described
below:

Name of the          Shares prior to the    Shares after the   % of shares after
shareholder                 transactions        transactions    the transactions

Burrill Life                   9,613,435                   0                   0
Sciences Capital
Fund, L.P.



Total                          9,613,435                   0                   0




The registered number of shares in Biotie Therapies Corp. is 176,003,931. Of
these shares 14,747,084 are held by the Company and the number of outstanding
shares and voting rights attached to the shares amounts thus to 161,256,847.

Turku, 19 January 2011

Timo Veromaa
President and CEO

For further information, please contact:

Virve Nurmi, Biotie Therapies Corp.
tel. +358 2 274 8900
e-mail:virve.nurmi@biotie.com

DISTRIBUTION
NASDAQ OMX Helsinki Ltd
Main Media
www.biotie.com


[HUG#1480784]